Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) independent director
In accordance with the company law of the people’s Republic of China, the securities law of the people’s Republic of China, the guiding opinions on the establishment of independent director system in listed companies, the stock listing rules of Shanghai Stock Exchange and other laws, regulations and normative documents of the China Securities Regulatory Commission, as well as the relevant provisions of the Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) articles of association, As an independent director of Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) (hereinafter referred to as “the company”), based on the principles of objectivity, fairness and impartiality, and on the basis of carefully reviewing the relevant proposals and materials received in advance, we express our prior approval opinions on the relevant matters as follows:
1、 Prior approval opinions on the company’s plan for daily connected transactions in 2022
The company’s daily plan for connected transactions in 2022 is formulated based on the changes in the market environment and the actual needs of the company’s production and operation, follows the principles of fairness, impartiality, voluntariness and integrity, and complies with relevant laws, regulations and normative documents such as guidelines for self discipline supervision of listed companies on Shanghai Stock Exchange No. 5 – transactions and connected transactions, as well as the provisions of the company’s management system for connected transactions. The pricing of related party transactions is fair, and there is no transfer of interests. The proportion of the estimated total amount of related party transactions to the estimated total amount of similar transactions of the company in 2022 is low, which will not lead to the company’s greater dependence on related parties, and there is no situation that damages the interests of the company or shareholders, especially the interests of non related shareholders and minority shareholders.
In conclusion, we agree to submit the matter to the 32nd meeting of the third board of directors of the company for deliberation.
2、 Prior approval opinions on the company’s reappointment of the audit institution in 2022
Lixin Certified Public Accountants (special general partnership) is a member of the international accounting network BDO and has the qualification for securities practice. In 2010, it became the first special general partnership certified public accountants firm in China to complete the restructuring. It has provided audit services for the company since 2012. In the process of practice, it adheres to the principles of independent, objective and fair audit. During its tenure as the company’s audit institution, We followed the independent auditing standards for Chinese certified public accountants, performed our duties diligently, carried out the audit work seriously and solidly, and completed all the audit work of the company.
In conclusion, we agree to submit the matter to the 32nd meeting of the third board of directors of the company for deliberation. (no text below)
